Cubist looks to dominate antibiotics game
This article was originally published in Scrip
Executive Summary
Cubist Pharmaceuticals could have multiple new drugs on the market within the next few years, making the hospital and acute care-focused company a dominant player in the antibiotics game based on its pipeline assets, acquisitions of Trius Therapeutics and Optimer Pharmaceuticals, and Cubist's advocacy for incentives to encourage antibiotic development.
You may also be interested in...
Finance Watch: Biopharma VC Explosion Extends To Tools, Services
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Amgen Hands Omecamtiv Back To Cytokinetics
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Need a specific report? 1000+ reports available
Buy Reports